1-isopropyl-2-methyl-3-pyrroline | 1109215-57-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-isopropyl-2-methyl-3-pyrroline
• 英文别名: 2-Methyl-1-propan-2-yl-2,5-dihydropyrrole
• CAS: 1109215-57-7
• 化学式: C₈H₁₅N
• 分子量: 125.214
• InChiKey: WLROHWNREJERLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  trans-3-bromo-1-isopropyl-2-methylpyrrolidine 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以58%的产率得到1-isopropyl-2-methyl-3-pyrroline
  参考文献：
  名称：

  通过2-（2-羟乙基）-3-甲基氮丙啶的扩环作用，顺式-3-氨基-2-甲基吡咯烷类化合物的 新加入†

  摘要：

  通过一种新的方案制备3-氨基-2-甲基吡咯烷，包括还原性闭环和γ-乙酰氧基-α-氯代酮亚胺对2-（2-羟乙基）-3-甲基氮丙啶的O-脱保护，然后环扩环。后者通过中间的双环叠氮鎓盐转变成3-溴吡咯烷，并通过叠氮化物将溴原子连续亲核取代成3-叠氮吡咯烷。叠氮化物部分的最终还原以高收率提供了3-氨基-2-甲基吡咯烷。因此，通过制备和进一步芳基化芳香化，开发了抗精神病性莫来那必利的新正式合成方法。顺式-3-氨基-1-苄基-2-甲基吡咯烷。

  DOI：

  10.1039/b816617j

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20110064698A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明揭示了Formula (I)的化合物，或其药用可接受的盐、酯或前药：这些化合物抑制RNA含有病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，同时也可作为抗病毒剂使用。本发明还涉及含有上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括这些化合物的药物组合物和用于治疗或预防受试者中需要这些化合物治疗的病毒（特别是HCV）感染的方法。
• Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity
  申请人：Kugimiya Akira

  公开号：US20090105274A1

  公开（公告）日：2009-04-23

  The present invention provides an indolecarboxylic acid derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (I): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X 1 =X 2 -X 3 =X 4 - is a formula of —C(R 1 )═C(R 2 )—C(R 3 )═C(R 4 )— etc.; X 5 is C(R 5 ) or N; R 1 , R 2 , R 3 , R 4 and R 5 is independently a hydrogen atom, a halogen atom etc; R 6 is a formula of -Z-R 10 etc. wherein Z is alkylene etc., and R 10 is carboxy etc.; R 7 is optionally substituted alkyloxy etc.; R 8 is independently a halogen atom etc.; R 9 is independently optionally substituted alkyl etc.; Y is a single bond etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or a solvate thereof.
• Azaindole Derivative Having PGD2 Receptor Antagonistic Activity
  申请人：Kugimiya Akira

  公开号：US20090197881A1

  公开（公告）日：2009-08-06

  The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases. A compound of the general formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X 1 =X 2 -X 3 =X 4 - is a formula of —C(R 1 )═C(R 2 )—C(R 3 )═N— etc.; R 1 , R 2 , R 3 , R 4 and R 5 are independently a hydrogen atom or a halogen atom etc.; R 6 is optionally substituted C1-C6 alkyloxy etc.; R 7 is independently a halogen atom etc.; R 8 is optionally substituted C1-C6 alky etc.; R 9 is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L 1 , L 2 and L 3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.
• CASPASE INHIBITOR PRODRUGS
  申请人：Durrant Steven

  公开号：US20110137037A1

  公开（公告）日：2011-06-09

  This invention relates to prodrugs of caspase inhibitors comprising of a furo[3,2-d]oxazolin-5-one moiety which, under specific conditions, can convert into biologically active compounds, particularly caspase inhibitors. This invention also relates to the processes for preparing these prodrugs of caspase inhibitors. This invention further relates to pharmaceutical compositions comprising said prodrugs and to the use thereof for the treatment of diseases related to inflammatory or degenerative conditions.
• INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：KUGIMIYA Akira

  公开号：US20120142687A1

  公开（公告）日：2012-06-07

  The present invention provides an indolecarboxylic acid derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (I): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of —X 1 ═X 2 —X 3 ═X 4 — is a formula of —C(R 1 )═C(R 2 )—C(R 3 )═C(R 4 )— etc.; X 5 is C(R 5 ) or N; R 1 , R 2 , R 3 , R 4 and R 5 is independently a hydrogen atom, a halogen atom etc; R 6 is a formula of —Z—R 10 etc. wherein Z is alkylene etc., and R 10 is carboxy etc.; R 7 is optionally substituted alkyloxy etc.; R 8 is independently a halogen atom etc.; R 9 is independently optionally substituted alkyl etc.; Y is a single bond etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or a solvate thereof.